Immunovant, Inc. (IMVT): Net Income
-$505.61M
Year ended 2026-03-31
-$538.22M
Trailing 12 months to 2026-06-30
| Period ended | Net Income | Change YoY | Source filing |
|---|---|---|---|
| 2026-03-31 | -$505.61M | n/m | 2026-05-20, From 2025-04-01 |
| 2025-03-31 | -$413.84M | n/m | 2026-05-20, From 2024-04-01 |
| 2024-03-31 | -$259.34M | n/m | 2026-05-20, From 2023-04-01 |
| 2023-03-31 | -$210.96M | n/m | 2025-05-29, From 2022-04-01 |
| 2022-03-31 | -$156.73M | n/m | 2023-05-22, From 2021-04-01 |
| 2021-03-31 | -$107.43M | n/m | 2022-06-08, From 2020-04-01 |
| 2020-03-31 | -$66.39M | n/m | 2021-06-01, From 2019-04-01 |
| 2019-03-31 | -$28.60M | n/a | 2020-06-29, From 2018-04-01 |
Net Income at similar companies
| Company | Year ended | Net Income | Change YoY |
|---|---|---|---|
| Immunovant, Inc. (IMVT) | 2026-03-31 | -$505.61M | n/m |
| Vir Biotechnology, Inc. (VIR) | 2025-12-31 | -$437.99M | n/m |
| Iovance Biotherapeutics, Inc. (IOVA) | 2025-12-31 | -$390.98M | n/m |
| Immunocore Holdings plc (IMCR) | 2025-12-31 | -$35.51M | n/m |
| Ginkgo Bioworks Holdings, Inc. (DNA) | 2025-12-31 | -$312.76M | n/m |
| Denali Therapeutics Inc. (DNLI) | 2025-12-31 | -$512.54M | n/m |
| CG Oncology, Inc. (CGON) | 2025-12-31 | -$161.00M | n/m |
| Novavax Inc (NVAX) | 2025-12-31 | $440.30M | n/m |
| Krystal Biotech, Inc. (KRYS) | 2025-12-31 | $204.83M | +129.7% |
Compare IMVT, VIR, IOVA, IMCR side by side · Screen every company in Biological Products, (No Diagnostic Substances) ↗